Literature DB >> 1675805

Metabolism and action of purine nucleoside analogs.

W Plunkett1, P P Saunders.   

Abstract

Recent investigations have identified many new purine nucleoside analogs that act as antimetabolites. This article focuses on the metabolism and mechanisms of action of tiazofurin, 3-deazaguanosine, neplanocin A, arabinosyladenine in combination with inhibitors of adenosine deaminase, arabinosyl-2-fluoroadenine, and 2-chloro-2'-deoxyadenosine, drugs that are either currently being evaluated in clinical trials or are close to that stage. The diverse metabolic requirements for activation, unique mechanisms of action, and differential biological activities of these compounds are characterized and evaluated for prospective therapeutic application.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675805     DOI: 10.1016/0163-7258(91)90057-s

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  24 in total

Review 1.  ABC transporters and their role in nucleoside and nucleotide drug resistance.

Authors:  Yu Fukuda; John D Schuetz
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

2.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Authors:  Bradley T Messmer; Davorka Messmer; Steven L Allen; Jonathan E Kolitz; Prasad Kudalkar; Denise Cesar; Elizabeth J Murphy; Prasad Koduru; Manlio Ferrarini; Simona Zupo; Giovanna Cutrona; Rajendra N Damle; Tarun Wasil; Kanti R Rai; Marc K Hellerstein; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

Review 3.  Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.

Authors:  Tadeusz Robak
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 4.  Cellular and clinical pharmacology of fludarabine.

Authors:  Varsha Gandhi; William Plunkett
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells.

Authors:  Paula X Fernández-Calotti; Mónica Lopez-Guerra; Dolors Colomer; Marçal Pastor-Anglada
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

6.  Cellular influx, efflux, and anabolism of 3-carboranyl thymidine analogs: potential boron delivery agents for neutron capture therapy.

Authors:  Elena Sjuvarsson; Vijaya L Damaraju; Delores Mowles; Michael B Sawyer; Rohit Tiwari; Hitesh K Agarwal; Ahmed Khalil; Sherifa Hasabelnaby; Ayman Goudah; Robin J Nakkula; Rolf F Barth; Carol E Cass; Staffan Eriksson; Werner Tjarks
Journal:  J Pharmacol Exp Ther       Date:  2013-09-04       Impact factor: 4.030

7.  Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors.

Authors:  William B Parker; Eric J Sorscher
Journal:  Curr Pharm Des       Date:  2017-11-08       Impact factor: 3.116

8.  Intracellular disposition of fludarabine triphosphate in human natural killer cells.

Authors:  Erica L Woodahl; Joanne Wang; Shelly Heimfeld; Brenda M Sandmaier; Jeannine S McCune
Journal:  Cancer Chemother Pharmacol       Date:  2008-09-10       Impact factor: 3.333

Review 9.  Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

10.  Fludarabine in the treatment of chronic lymphocytic leukemia: a review.

Authors:  Francesca Ricci; Alessandra Tedeschi; Enrica Morra; Marco Montillo
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.